|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: EXD2 |
Gene summary for EXD2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | EXD2 | Gene ID | 55218 |
| Gene name | exonuclease 3'-5' domain containing 2 | |
| Gene Alias | C14orf114 | |
| Cytomap | 14q24.1 | |
| Gene Type | protein-coding | GO ID | GO:0000724 | UniProtAcc | Q9NVH0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55218 | EXD2 | LZE4T | Human | Esophagus | ESCC | 1.16e-05 | 2.07e-01 | 0.0811 |
| 55218 | EXD2 | LZE5T | Human | Esophagus | ESCC | 4.40e-02 | 1.97e-01 | 0.0514 |
| 55218 | EXD2 | LZE22T | Human | Esophagus | ESCC | 9.15e-03 | 2.83e-01 | 0.068 |
| 55218 | EXD2 | LZE24T | Human | Esophagus | ESCC | 9.73e-10 | 2.27e-01 | 0.0596 |
| 55218 | EXD2 | P2T-E | Human | Esophagus | ESCC | 4.22e-11 | 1.58e-01 | 0.1177 |
| 55218 | EXD2 | P4T-E | Human | Esophagus | ESCC | 6.42e-06 | 1.45e-01 | 0.1323 |
| 55218 | EXD2 | P8T-E | Human | Esophagus | ESCC | 1.43e-14 | 2.24e-01 | 0.0889 |
| 55218 | EXD2 | P10T-E | Human | Esophagus | ESCC | 4.39e-15 | 2.41e-01 | 0.116 |
| 55218 | EXD2 | P11T-E | Human | Esophagus | ESCC | 6.13e-12 | 4.15e-01 | 0.1426 |
| 55218 | EXD2 | P12T-E | Human | Esophagus | ESCC | 3.73e-24 | 4.39e-01 | 0.1122 |
| 55218 | EXD2 | P15T-E | Human | Esophagus | ESCC | 1.66e-18 | 3.75e-01 | 0.1149 |
| 55218 | EXD2 | P16T-E | Human | Esophagus | ESCC | 4.31e-12 | 2.09e-01 | 0.1153 |
| 55218 | EXD2 | P20T-E | Human | Esophagus | ESCC | 1.02e-06 | 1.65e-01 | 0.1124 |
| 55218 | EXD2 | P21T-E | Human | Esophagus | ESCC | 6.19e-07 | 1.16e-01 | 0.1617 |
| 55218 | EXD2 | P22T-E | Human | Esophagus | ESCC | 5.12e-10 | 1.65e-01 | 0.1236 |
| 55218 | EXD2 | P23T-E | Human | Esophagus | ESCC | 1.71e-06 | 1.75e-01 | 0.108 |
| 55218 | EXD2 | P24T-E | Human | Esophagus | ESCC | 8.14e-12 | 1.54e-01 | 0.1287 |
| 55218 | EXD2 | P26T-E | Human | Esophagus | ESCC | 1.30e-17 | 2.36e-01 | 0.1276 |
| 55218 | EXD2 | P27T-E | Human | Esophagus | ESCC | 1.08e-21 | 2.86e-01 | 0.1055 |
| 55218 | EXD2 | P28T-E | Human | Esophagus | ESCC | 2.42e-05 | 1.15e-01 | 0.1149 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00062604 | Esophagus | ESCC | DNA replication | 181/8552 | 260/18723 | 3.55e-15 | 2.05e-13 | 181 |
| GO:00905013 | Esophagus | ESCC | RNA phosphodiester bond hydrolysis | 110/8552 | 152/18723 | 1.95e-11 | 6.81e-10 | 110 |
| GO:00903053 | Esophagus | ESCC | nucleic acid phosphodiester bond hydrolysis | 163/8552 | 261/18723 | 3.07e-08 | 5.73e-07 | 163 |
| GO:00062612 | Esophagus | ESCC | DNA-dependent DNA replication | 100/8552 | 151/18723 | 2.61e-07 | 3.94e-06 | 100 |
| GO:00905033 | Esophagus | ESCC | RNA phosphodiester bond hydrolysis, exonucleolytic | 35/8552 | 42/18723 | 5.35e-07 | 7.11e-06 | 35 |
| GO:00063024 | Esophagus | ESCC | double-strand break repair | 152/8552 | 251/18723 | 1.33e-06 | 1.62e-05 | 152 |
| GO:00063101 | Esophagus | ESCC | DNA recombination | 168/8552 | 305/18723 | 5.58e-04 | 3.05e-03 | 168 |
| GO:00007241 | Esophagus | ESCC | double-strand break repair via homologous recombination | 79/8552 | 138/18723 | 4.05e-03 | 1.62e-02 | 79 |
| GO:00007251 | Esophagus | ESCC | recombinational repair | 80/8552 | 140/18723 | 4.10e-03 | 1.63e-02 | 80 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| EXD2 | SNV | Missense_Mutation | novel | c.1378N>C | p.Thr460Pro | p.T460P | Q9NVH0 | protein_coding | tolerated(0.11) | benign(0.033) | TCGA-A2-A0CS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
| EXD2 | SNV | Missense_Mutation | novel | c.337N>C | p.Asn113His | p.N113H | Q9NVH0 | protein_coding | deleterious(0.01) | possibly_damaging(0.804) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| EXD2 | SNV | Missense_Mutation | c.1443C>G | p.Phe481Leu | p.F481L | Q9NVH0 | protein_coding | deleterious(0.04) | benign(0.138) | TCGA-AO-A0J4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| EXD2 | insertion | Frame_Shift_Ins | novel | c.1042_1043insTGGGT | p.Ser348LeufsTer43 | p.S348Lfs*43 | Q9NVH0 | protein_coding | TCGA-AN-A0FD-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| EXD2 | insertion | Frame_Shift_Ins | novel | c.1043_1044insATTTGTTATTTTATTTTTGAGTTTTAGGAATTCTT | p.Ala349PhefsTer52 | p.A349Ffs*52 | Q9NVH0 | protein_coding | TCGA-AN-A0FD-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| EXD2 | SNV | Missense_Mutation | rs762151815 | c.676N>T | p.Arg226Cys | p.R226C | Q9NVH0 | protein_coding | deleterious(0.03) | probably_damaging(0.99) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| EXD2 | SNV | Missense_Mutation | rs753418619 | c.1336N>A | p.Glu446Lys | p.E446K | Q9NVH0 | protein_coding | tolerated(0.1) | benign(0.101) | TCGA-AA-3693-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| EXD2 | SNV | Missense_Mutation | c.376N>C | p.Met126Leu | p.M126L | Q9NVH0 | protein_coding | tolerated(0.57) | benign(0) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| EXD2 | SNV | Missense_Mutation | c.1651N>T | p.Ile551Phe | p.I551F | Q9NVH0 | protein_coding | deleterious(0.01) | possibly_damaging(0.447) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD | |
| EXD2 | SNV | Missense_Mutation | novel | c.947G>T | p.Arg316Ile | p.R316I | Q9NVH0 | protein_coding | deleterious(0.01) | benign(0.294) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |